Drug-induced liver injury from selective androgen receptor modulators, anabolic-androgenic steroids and bodybuilding supplements in Australia

被引:3
|
作者
Nash, Emily [1 ,2 ]
Nicoll, Amanda [3 ]
Batt, Nicholas [3 ]
George, Jacob [4 ,5 ]
Perananthan, Varan [6 ]
Prince, David [7 ,8 ]
Wallace, Michael [9 ,10 ]
Gow, Paul [11 ]
Vaz, Karl [11 ]
Chitturi, Shivakumar [12 ]
Flores, Joan Ericka [12 ]
Braund, Alicia [13 ]
Bonnichsen, Mark [7 ]
Riordan, Stephen [14 ]
Humphris, Jeremy [15 ]
Duong, Tuan [15 ]
Mckenzie, Catriona [16 ]
Liu, Ken [1 ,2 ]
Strasser, Simone I. [1 ,2 ]
机构
[1] Royal Prince Alfred Hosp, AW Morrow Gastroenterol & Liver Ctr, Missenden Rd, Sydney, NSW, Australia
[2] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
[3] Eastern Hlth, Melbourne, Vic, Australia
[4] Westmead Hosp, Westmead Millennium Inst, Storr Liver Ctr, Westmead, NSW, Australia
[5] Univ Sydney, Sydney, NSW, Australia
[6] Westmead Hosp, Dept Gastroenterol & Hepatol, Westmead, NSW, Australia
[7] Liverpool Hosp, Dept Gastroenterol & Liver, Sydney, NSW, Australia
[8] Univ New South Wales, Fac Med, Sydney, NSW, Australia
[9] Sir Charles Gairdner Hosp, Perth, WA, Australia
[10] Univ Western Australia, Med Sch, Perth, WA, Australia
[11] Austin Hlth, Melbourne, Vic, Australia
[12] Canberra Hosp, Canberra, ACT, Australia
[13] Gold Coast Univ Hosp, Gold Coast, Qld, Australia
[14] Prince Wales Hosp, Sydney, NSW, Australia
[15] Wollongong Hosp, Wollongong, NSW, Australia
[16] NSW Hlth Pathol, Sydney, NSW, Australia
关键词
PHENOTYPE; SAFETY;
D O I
10.1111/apt.17906
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BackgroundReports of DILI due to herbal and dietary supplements have been increasing over time.AimsTo characterise clinical, laboratory and histopathological phenotypes and outcomes of drug-induced liver injury (DILI) due to anabolic-androgenic steroids (AAS), selective androgen receptor modulators (SARMs), and bodybuilding supplements (BBS) in Australia.MethodsRetrospective case series. Patients presented to nine Australian tertiary hospitals, 2017-2023. DILI was defined biochemically and patients were included if their treating physician attributed DILI to preceding use of AAS, SARMs or BBS. Primary endpoint was time to normalisation of liver biochemistry. Secondary endpoints were hospitalisation for investigation or management of DILI, death attributable to liver injury, and liver transplantation.ResultsTwenty-three cases of DILI were identified, involving 40 drugs: 18 AAS, 14 SARMs and eight BBS. Patients were predominantly male (22/23), with median age 30 years (IQR 26-42). Most were symptomatic (21/23). Median latency of onset was 58 days (IQR 28-112 days) from drug commencement. Most patients (17/23) were admitted to hospital. Based on updated Roussel Uclaf Causality Assessment Method, DILI was possible in 17/23, probable in 2/23 and unlikely in 4/23. Median time to normalisation of liver biochemistry was 175 days (IQR 70-292 days) from presentation. Three (3/23) were treated with corticosteroids, 14/23 were treated for itch, and one (1/23) underwent liver transplantation. There were no deaths.ConclusionsThe prognosis of DILI from AAS, SARMs and BBS is good although liver transplantation may rarely be required. A detailed drug history is important in uncovering DILI due to these supplements. Liver injury is an important consideration of these drugs. Prognosis with supportive care is good, with normalisation of liver biochemistry the most likely outcome, although hospitalisation may be required and, rarely, liver transplantation. A detailed drug and dietary supplement history is important in elucidating causes of DILI.image
引用
收藏
页码:953 / 961
页数:9
相关论文
共 50 条
  • [1] Drug-induced liver injury from anabolic-androgenic steroids, selective androgen receptor modulators, and bodybuilding supplements in Australia
    Nash, E.
    Nicoll, A.
    Batt, N.
    Prince, D.
    Wallace, M.
    Gow, P.
    Vaz, K.
    Chitturi, S.
    Flores, E.
    Braund, A.
    Bonnichsen, M.
    Riordan, S.
    Duong, T.
    Liu, K.
    Strasser, S.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2022, 37 : 100 - 101
  • [2] Drug-Induced Liver Injury by Selective Androgenic Receptor Modulators
    Flores, Joan Ericka
    Chitturi, Shivakumar
    Walker, Sarah
    HEPATOLOGY COMMUNICATIONS, 2020, 4 (03) : 450 - 452
  • [3] Anabolic-androgenic steroids and liver injury
    Sanchez-Osorio, Magdalena
    Duarte-Rojo, Andres
    Martinez-Benitez, Braulio
    Torre, Aldo
    Uribe, Misael
    LIVER INTERNATIONAL, 2008, 28 (02) : 278 - 282
  • [4] Androgenic-Anabolic Steroids: From the Gym to Drug-Induced Liver Injury
    Alves, Ana Sofia
    Perdigao, Sofia
    Morais, Sandra
    Sousa, Cristiana
    Salvador, Fernando
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (09)
  • [5] Mission Compromised? Drug-Induced Liver Injury From Prohormone Supplements Containing Anabolic-Androgenic Steroids in Two Deployed US Service Members
    Magee, Charles D.
    Witte, Stephen
    Kwok, Ryan M.
    Deuster, Patricia A.
    MILITARY MEDICINE, 2016, 181 (09) : E1169 - E1171
  • [6] Harmful Gains: Drug-Induced Liver Injury From Selective Androgen Receptor Modulators
    Baliss, Michelle
    Kline, Kevin
    Merwat, Sheharyar
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S1421 - S1421
  • [7] Comparative safety evaluation of selective androgen receptor modulators and anabolic androgenic steroids
    Choi, Seul Min
    Lee, Byung-Mu
    EXPERT OPINION ON DRUG SAFETY, 2015, 14 (11) : 1773 - 1785
  • [8] Profiling of anabolic androgenic steroids and selective androgen receptor modulators for interference with adrenal steroidogenesis
    Patt, Melanie
    Beck, Katharina R.
    Di Marco, Tobias
    Jager, Marie-Christin
    Gonzalez-Ruiz, Victor
    Boccard, Julien
    Rudaz, Serge
    Hartmann, Rolf W.
    Salah, Mohamed
    van Koppen, Chris J.
    Grill, Matthias
    Odermatt, Alex
    BIOCHEMICAL PHARMACOLOGY, 2020, 172
  • [9] A Case of Anabolic Androgenic Steroid Drug-Induced Liver Injury
    Liu, Benjamin D.
    Gorvet, Marissa
    Patel, Neil D.
    Niu, Bolin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S2276 - S2276
  • [10] Androgenic-anabolic steroid drug-induced liver injury
    Ding, N. S.
    De Cruz, P.
    Lim, L.
    Thompson, A.
    Desmond, P.
    INTERNAL MEDICINE JOURNAL, 2013, 43 (02) : 215 - 216